Amphista & Bristol Myers Squibb to Collaborate & Leverage Proprietary Eclipsys Targeted Protein Degradation Platform to Develop Novel Protein Degrading Therapeutics

Amphista & Bristol Myers Squibb to Collaborate & Leverage Proprietary Eclipsys Targeted Protein Degradation Platform to Develop Novel Protein Degrading Therapeutics
4 May 2022
Drug Development & Delivery – View full story